# Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

> **NCT01237873** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 150 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Ali/Amlo 150/2.5 mg

## Key facts

- **NCT ID:** NCT01237873
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237873, "Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT01237873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*